KALV
KalVista Pharmaceuticals Inc.
$13.08
-$0.02(-0.15%)
36
Overall
--
Value
36
Tech
--
Quality
Market Cap
$682.06M
Volume
332.78K
52W Range
$7.30 - $17.28
Target Price
$31.67
Order:
Income Statement
| Metric | Trend | Chart | 2020 Apr | 2021 Apr | 2022 Apr | 2023 Apr | 2024 Apr | 2025 Apr |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | $12.7M | -- | -- | -- | -- | -- | ||
| Total Revenue | $12.7M | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||
| Gross Profit | $12.7M | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $53.2M | $57.9M | $96.6M | $110.9M | $140.4M | $188.0M | ||
| Research & Development | $40.2M | $41.3M | $70.2M | $80.3M | $86.2M | $71.7M | ||
| Research Expense | $40.2M | $41.3M | $70.2M | $80.3M | $86.2M | $71.7M | ||
| Selling, General & Administrative | $13.0M | $16.6M | $26.4M | $30.6M | $54.3M | $116.3M | ||
| General & Administrative Expenses | $13.0M | $16.6M | $26.4M | $30.6M | $54.3M | $116.3M | ||
| Depreciation & Amortization | $512.0K | $500.0K | $600.0K | $700.0K | $800.0K | -- | ||
| Depreciation & Amortization | $512.0K | $500.0K | $600.0K | $700.0K | -- | -- | ||
| Other Operating Expenses | $857.0K | $1.1M | $1.9M | $2.0M | -- | -- | ||
| OPERATING INCOME | ||||||||
| Operating income | $-40.5M | $-57.9M | $-96.6M | $-110.9M | $-140.4M | $-188.0M | ||
| EBITDA | $-28.5M | $-45.1M | $-79.2M | $-91.2M | $-125.8M | $-173.3M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | $5.8M | ||
| Intinc | $1.8M | $903.0K | $1.1M | $2.2M | $3.9M | $6.4M | ||
| Net Non-Operating Interest Income/Expense | $1.8M | $903.0K | $1.1M | $2.2M | $3.9M | $650.0K | ||
| Gain on Sale of Securities | -- | -- | -- | $-100.0K | -- | -- | ||
| Other Income/Expense | $-9.8M | $-9.9M | $13.2M | $-15.6M | $-9.8M | $-4.8M | ||
| Other Special Charges | $9.8M | $9.9M | $14.7M | $15.6M | $9.8M | $4.8M | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-29.2M | $-46.2M | $-82.3M | $-92.9M | $-126.6M | $-174.3M | ||
| Pre-Tax Income | $-29.2M | $-46.2M | $-82.3M | $-92.9M | $-126.6M | $-180.1M | ||
| INCOME TAX | ||||||||
| Tax Provision | $-124.0K | -- | -- | -- | -- | $3.4M | ||
| NET INCOME | ||||||||
| Net Income | $-29.1M | $-46.2M | $-82.3M | $-92.9M | $-126.6M | $-183.4M | ||
| Net Income (Continuing Operations) | $-29.1M | $-46.2M | $-82.3M | $-92.9M | $-126.6M | $-183.4M | ||
| Net Income (Discontinued Operations) | $-29.1M | $-46.2M | $-82.3M | $-92.9M | $-126.6M | $-183.4M | ||
| Net Income (Common Stockholders) | $-29.1M | $-46.2M | $-82.3M | $-92.9M | $-126.6M | $-183.4M | ||
| Normalized Income | -- | $-36.5M | -- | -- | -- | $-178.3M | ||
| TOTALS | ||||||||
| Total Expenses | $53.2M | $57.9M | $96.6M | $110.9M | $140.4M | $188.0M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $17.7M | $19.1M | $24.5M | $27.9M | $36.8M | $49.7M | ||
| Average Shares Outstanding (Diluted) | $17.7M | $19.1M | $24.5M | $27.9M | $36.8M | $49.7M | ||
| Shares Outstanding | $17.8M | $24.4M | $24.6M | $34.2M | $42.7M | $50.0M | ||
| Basic EPS | $-1.64 | $-2.42 | $-3.36 | $-3.33 | $-3.44 | $-3.69 | ||
| Basic EPS (Continuing Operations) | $-1.64 | $-2.42 | $-3.36 | $-3.33 | $-3.44 | $-3.69 | ||
| Diluted EPS | $-1.64 | $-2.42 | $-3.36 | $-3.33 | $-3.44 | $-3.69 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-3.36 | $-3.33 | $-3.44 | $-3.69 | ||
| OTHER METRICS | ||||||||
| Other Gand A | $13.0M | $16.6M | $26.4M | $30.6M | $54.3M | $116.3M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KALV | $13.08 | -0.2% | 332.78K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get KalVista Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW